Gemini Therapeutics

24 articles with Gemini Therapeutics

• Gemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

  4/13/2021

  Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced the grant of an inducement award to Brian Piekos, Gemini’s Chief Financial Officer and the grant of an inducement award to Dr. Sam Barone, Gemini’s Chief Medical Officer.

• Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer

  4/12/2021

  Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Samuel Barone, M.D., as Gemini’s Chief Medical Officer, effective immediately.

• Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

  2/19/2021

  Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the SVB Leerink 10th Annual Global Healthcare Conference

• 

  BioSpace Movers & Shakers, Feb. 12

  2/12/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry Age-Related Macular Degeneration (AMD) in Patients with High-Risk Genetic Variants

  2/10/2021

  Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the completion of enrollment in its Phase 2a

• Gemini Therapeutics Appoints Brian Piekos as Chief Financial Officer

  2/9/2021

  Gemini Therapeutics, Inc., (Nasdaq: GMTX) a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Brian Piekos has been appointed to serve as Chief Financial Officer.

• Gemini Therapeutics Debuts as Publicly Traded Precision Medicine Company Focused on Age-Related Macular Degeneration

  2/8/2021

  - Business combination transaction with FS Development Corp., a special purpose acquisition company sponsored by Foresite Capital, completed on February 5, 2021 – - Combined company renamed Gemini Therapeutics, Inc. – - Common stock commences trading today on the Nasdaq Global Market under ticker symbol “GMTX” –

• 

  Gemini Therapeutics Hits the Nasdaq Following SPAC Merger

  2/8/2021

  The combined company will be called Gemini Therapeutics, Inc. and will trade under the ticker symbol, GMTX.

• Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy

  2/1/2021

  Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined AMD, today announced the commencement of a Phase 2a trial advancing GEM103 as a potential add-on therapy for patients suffering from wet AMD who have, or may be at risk for, macular atrophy (MA) but require ongoing anti-vascular endothelial growth factor

• Gemini Therapeutics Announces FDA Fast Track Designation Granted for GEM103 for the Treatment of Dry Age-Related Macular Degeneration (AMD) in Patients With Complement Factor H (CFH) Loss of Function Gene Variants

  1/7/2021

  Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that GEM103, the Company’s investigational treatment for dry AMD, has been granted Fast Track designation by the United States Food and Drug Administration (FDA). Gemini is evaluating GEM103, a recombinant, human complement factor H (CFH), for it

• Genosity Enters Into an Agreement With Gemini Therapeutics to Develop a Diagnostic and Implement Testing to Support Gemini’s Age-Related Macular Degeneration Trial

  12/16/2020

  Genosity , Inc, a biotechnology company offering novel software and laboratory solutions to enable development and deployment of complex NGS assays, announced an agreement with Gemini Therapeutics to conduct molecular profiling in support of clinical trial patient selection and stratification for Gemini’s GEM103 program in age-related macular degeneration (AMD). Under this agreement, Gemini will provide samples from prosp

•  Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Study

  11/13/2020

    Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Study   - A single intravitreal injection of GEM103 (recombinant human complement Factor H) met safety endpoint - - No dose-limiting toxicities, and no treatment-related adverse events in patients with genetically defined dry age-related macular degeneration (AMD) and central geographic atrophy (GA) -

• Gemini Therapeutics to Participate in Upcoming Investor Conferences

  11/10/2020

  Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyenberg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the following investor conferences in November: Stifel 2020 Virtual Healthcare Conference Date: Tuesday, November 17

• Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular Degeneration

  10/15/2020

  Leading institutional investors commit $95 million through a common stock private investment in public equity (“PIPE”) led by Foresite Capital, as well as Fidelity Management & Research Company LLC, Wellington Management, Boxer Capital of Tavistock Group, Alyeska Investment Group, L.P., Suvretta Capital Management, CVF, DAFNA Capital, and Acorn Bioventures – - Total proceeds from this transaction are expected to be approximately $216 million, com

• Gemini Therapeutics Enrolls First Patient in Phase 2a Study of GEM103 for Dry Age-related Macular Degeneration

  9/10/2020

  -  Enrollment initiated in Phase 1 MAD study in patients with high-risk genetic variants for dry AMD –    -  Phase 1 topline results demonstrate promising safety profile, with no treatment-related adverse events as well as PK and biomarker changes in genetically defined dry AMD -   CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined Age-

• Gemini Therapeutics Appoints Dr. Tuyen Ong as Independent Director

  8/27/2020

  Ophthalmology innovator brings more than 20 years of clinical and drug development experience to the Board of Directors

• Gemini Therapeutics Appoints Marc E. Uknis, MD, FACS as Chief Medical Officer

  5/7/2020

  Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced that Marc E. Uknis MD, FACS has been appointed to serve as Chief Medical Officer, effective today. Dr. Uknis brings more than 35 years of experience in industry and academia in research programs across various areas including surgery,

• Gemini Therapeutics Appoints David Lubner as Independent Director

  4/28/2020

  Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration and linked ocular disorders, announced that David Lubner has been appointed to serve as an independent member of its Board of Directors.

• Gemini Therapeutics and Singapore Eye Research Institute Enter Into Research Collaboration to Explore New Targets for Age-related Macular Degeneration

  2/26/2020

  Feb. 26, 2020 12:00 UTC CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced a collaboration with the Singapore Eye Research Institute (SERI) to expand knowledge and identify new targets associated with AMD. Under the terms of the agreement, SERI and Gemini will explore the link between genetic and poten

• Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular Degeneration

  1/9/2020

  Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry age-related macular degeneration (AMD) and linked ocular disorders, today announced it has initiated enrollment in its Phase 1 study of GEM103, a recombinant, native Complement Factor H (CFH) for the treatment of dry age-related macular degeneration